Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS ...

Semaglutide (Ozempic) is 1 of 15 medications that will be included in yearly price negotiations between Medicare and ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular semaglutide medicines as one of the 15 additional drugs covered under ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden adds Ozempic to list for Medicare price negotiationIn one of its last actions, the Biden ...